Vyome Holdings (HIND) Operating Income (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Operating Income of -$1.1 million for Q1 2026, down 467.81% year-over-year from $307203.6 in Q1 2025, and up 16.61% quarter-over-quarter from -$1.4 million in Q4 2025.
Vyome Holdings (HIND) Operating Income (2015 - 2026) Analysis & Trends
Vyome Holdings' Operating Income history runs 12 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Operating Income fell 467.81% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$13.8 million (down 395.39% YoY), while the FY2025 annual figure was -$10.5 million, down 938.67% from the prior year.
- Operating Income for Q1 2026 stood at -$1.1 million, up from -$1.4 million in the prior quarter.
- The five-year high for Operating Income was -$198998.0 in Q1 2025, with the low at -$16.7 million in Q4 2022.
- The 5-year median for Operating Income is -$2.8 million (2025), against an average of -$4.7 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income jumped 92.76% in 2024, then sank 2951.59% in 2025.
- Vyome Holdings' Operating Income stood at -$16.7 million in 2022, then jumped by 88.65% to -$1.9 million in 2023, then soared by 86.49% to -$256006.0 in 2024, then slumped by 429.31% to -$1.4 million in 2025, then grew by 16.61% to -$1.1 million in 2026.
- Business Quant data shows HIND's Operating Income at -$1.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 133.12 Mn |
| 10 | Vyome Holdings | 15.51 Mn | 7.62 Mn | 11,658.00 | -862,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -862,566.00 |
| Mar 31, 2026 | -1.13 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -8.57 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -198,998.00 |
| Dec 31, 2024 | -256,006.00 |
| Sep 30, 2024 | -280,978.00 |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.21 Mn |
| Dec 31, 2023 | -1.90 Mn |
| Sep 30, 2023 | -3.88 Mn |
| Jun 30, 2023 | -3.98 Mn |
| Mar 31, 2023 | -5.63 Mn |
| Dec 31, 2022 | -16.69 Mn |
| Sep 30, 2022 | -12.30 Mn |
| Jun 30, 2022 | -9.24 Mn |
| Mar 31, 2022 | -8.11 Mn |
| Dec 31, 2021 | -37.52 Mn |
| Sep 30, 2021 | -14.42 Mn |